{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-159845","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2023-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.348376+00:00","generated_at":"2026-06-14T08:33:16.631755+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Tyra Biosciences stockholders elect three Class II directors, ratify E&Y as auditor","bullets":["Stockholders elected Isan Chen (37.3M for), Gilla Kaplan (37.6M for), and Robert More (37.6M for) as Class II directors to serve until 2026.","Ratification of Ernst & Young as independent auditor for FY 2023 passed with 40,984,756 for, 625 against, and 1,819 abstentions.","Broker non-votes were 3,109,065 for director elections and 0 for auditor ratification.","Annual meeting held on May 31, 2023; all proposals approved by substantial majorities."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-159845","json":"https://secwatch.observer/filing/0001193125-23-159845.json","markdown":"https://secwatch.observer/filing/0001193125-23-159845.md","text":"https://secwatch.observer/filing/0001193125-23-159845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312523159845/0001193125-23-159845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312523159845/d509793d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T08:33:16.631755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6116e14eabdd1272c44433a2a07c0eebbf48ff4","claim":"Tyra Biosciences, Inc. shareholders approved Election of three Class II directors to serve until the 2026 Annual Meeting of Stockholders at the 2023-05-31 meeting.","evidence_excerpt":"1. The election of three directors to serve as Class II directors for a three-year term to expire at the 2026 Annual Meeting of Stockholders. The following three Class II directors were elected by the votes indicated: For Withheld Broker Non-Votes Isan Chen, M.D. 37,336,370 541,765 3,109,065 Gilla Kaplan, Ph.D. 37,581,968 296,167 3,109,065 Robert More 37,571,418 306,717 3,109,065","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312523159845/0001193125-23-159845-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-31"}],"fact_type":"shareholder_vote"},{"claim_id":"f0496b14c4107a1675f5e5d0ea7e144929cad6d9","claim":"Tyra Biosciences, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-31 meeting.","evidence_excerpt":"2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 40,984,756 625 1,819 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312523159845/0001193125-23-159845-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-31"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}